Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 11/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398987 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5492996 | 0.87 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5493006 | 0.87 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8115464 | 0.86 | ADORA2A (0.81) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8115461 | 0.86 | ADORA2A (0.81) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL13084540 | 0.86 | ADORA2A (0.75) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL2775059 | 0.86 | ADORA2A (0.75) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL2291656 | 0.85 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8115549 | 0.85 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL30862346 | 0.85 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906518-B2 | [(3aR,4R,6R,6aR)-6-(6-amino-2-methoxy-9H-purin-9yl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]methanol; improved oral absorption | CBT DEVELOPMENT LIMITED (GB) | 2011-03-15 | — | — | US | disclosed |
| EP-2066685-B1 | NOVEL 2',3'-METHYLIDENE ACETYL ADENOSINE PRODRUGS FOR USE AS PRODRUGS FOR ADENOSINE RECEPTOR AGONISTS | CBT DEV LTD (GB) | 2011-03-02 | — | — | EP | disclosed |
| US-7820811-B2 | Pro-drugs of adenosine receptor agonists | CBT DEVELOPMENT LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| EP-2081932-A2 | 2-O'-METHYLADENOSINE DERIVATIVES AND THEIR USE AS AGONISTS OR ANTAGONISTS OF AN ADENOSINE RECEPTOR | BIOVITRUM AB (publ) (SE) | 2009-07-29 | — | — | EP | disclosed |
| EP-2066685-A2 | NOVEL 2',3'-METHYLIDENE ACETYL ADENOSINE PRODRUGS FOR USE AS PRODRUGS FOR ADENOSINE RECEPTOR AGONISTS | BIOVITRUM AB (publ) (SE) | 2009-06-10 | — | — | EP | disclosed |
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080027081-A1 | Therapeutic compounds | BIOVITRUM AB (PUBL) | 2008-01-31 | — | — | US | disclosed |
| US-20080009461-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2008000744-A2 | 2-0'-METHYLADEN0SINE DERIVATIVES AND THEIR USE AS AGONISTS OR ANTAGONISTS OF AN ADENOSINE RECEPTOR | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000743-A2 | NOVEL 2',3'-METHYLIDENE ACETYL ADENOSINE PRODRUGS FOR USE AS PRODRUGS FOR ADENOSINE RECEPTOR AGONISTS | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | disclosed |
| EP-1749016-A2 | ADENOSINE RECEPTOR AGONISTS | Cambridge Biotechnology Ltd (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005084653-A2 | ADENOSINE RECEPTOR AGONISTS | CAMBRIDGE BIOTECHNOLOGY LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | ADORA3, ADORA2B, P2RX3 | ADORA2A 9/4885ADORA2B 2/4885ADORA3 1/4885 |
| US-20080009461-A1 | Therapeutic compounds | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA2B 2/4885ADORA3 4/4885 |
| US-20080027081-A1 | Therapeutic compounds | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.